Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Impact of lenalidomide pre-apheresis on markers of T cell fitness and pharmacodynamic biomarkers in newly diagnosed multiple myeloma patients with suboptimal response to autologous stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJ G WongSNSonash NayeeDBDebashree Basudhar

Discussion

Loading...

Member takes

Overview

Trial demonstrates lenalidomide pre-apheresis improves T cell fitness and outcomes in newly diagnosed multiple myeloma patients.

Key Points

  • This analysis evaluates the effect of lenalidomide pre-apheresis on T cell fitness and pharmacodynamic markers in newly diagnosed multiple myeloma patients post-autologous stem cell transplantation.
  • Phase 2 multicenter trial with cross-cohort analysis
  • Immune profiling of peripheral blood mononuclear cells using CyTOF
  • Cytokine and chemokine profiling
  • Proteomic analysis with OLINK 3K panel
  • Assessment of drug product characteristics and cellular kinetics
  • Cohort 3 showed improved T cell fitness compared to Cohort 2c
  • Higher levels of IL2 and differential expression of over 200 analytes in Cohort 3
  • 93.3% of Cohort 3 patients had superior clearance of sBCMA, compared to 77.4% in Cohort 2c

Cite This Study

Wong et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cffahttps://doi.org/10.1182/blood-2025-95
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma2025
  2. 2Idecabtagene vicleucel and endogenous T‐cell phenotypes linked to progression‐free survival in relapsed multiple myeloma2026
  3. 3BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma2025
  4. 4CAR-T cells manufactured after multiple myeloma triplet or quadruplet induction therapy have reduced functionality and an altered composition2025
  5. 5The dynamic landscape of immune environment for MM patients receiving T cell redirectiing therapies2025